An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe.

Détails

ID Serval
serval:BIB_DCD242EEF62B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe.
Périodique
Pharmacogenetics and Genomics
Auteur(s)
Orkin Chloe, Wang Jianmin, Bergin Colm, Molina Jean-Michel, Lazzarin Adriano, Cavassini Matthias, Esser Stefan, Gomez Sirvent Juan-Luis, Pearce Helen
ISSN
1744-6880[electronic], 1744-6872[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
20
Numéro
5
Pages
307-314
Langue
anglais
Résumé
OBJECTIVES: HLA-B*5701 is a major histocompatibility complex class I allele associated with an immunologically-mediated hypersensitivity reaction to abacavir. The objectives of this study were to evaluate HLA-B*5701 prevalence among European, HIV-1-infected patients and to compare the local and central laboratory screening results. METHODS: Data were combined from six multicentre, prospective studies involving 10 European countries in which HIV-1-infected patients (irrespective of treatment experience or previous HLA-B*5701 screening), >or=18 years of age, were evaluated for HLA-B*5701 carriage, determined by the central and local laboratory methods. RESULTS: A total of 9720 patients from 272 centres were included in the analysis. The overall estimate of HLA-B*5701 prevalence in Europe was 4.98%, with country-specific estimates ranging from 1.53 to 7.75%. HLA-B*5701 prevalence was highest in the self-reported white population (6.49%) and lowest in the black population (0.39%). Local laboratory results had a high specificity (99.9%) and sensitivity (99.2%) when compared with the central laboratory results. CONCLUSION: This study supports data from previous studies regarding the prevalence of HLA-B*5701 in the HIV population and the variation of HLA-B*5701 prevalence between different racial groups. The high specificity and sensitivity of local laboratory results, suggests that clinicians can be confident in using local laboratories for pretreatment HLA-B*5701 screening. However, it is essential that local laboratories participate in HLA-B*5701-specific quality assurance programs to maintain 100% sensitivity. In HIV-infected patients, pretreatment HLA-B*5701 screening may allow more informed decisions regarding abacavir use and has the potential to significantly reduce the frequency of abacavir-related hypersensitivity reactions and costs associated with managing these reactions.
Mots-clé
Abacavir, Histocompatibility Complex Class I, HLA-B*5701, Hypersensitivity, Prevalence, Pretreatment Screening, Abacavir Hypersensitivity, Infected Patients, Association, Therapy, Cohort
Pubmed
Web of science
Création de la notice
06/05/2010 13:40
Dernière modification de la notice
20/08/2019 16:01
Données d'usage